Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
26.27
-0.11 (-0.42%)
At close: Sep 24, 2026, 4:00 PM EDT
26.25
-0.02 (-0.08%)
After-hours: Sep 24, 2026, 7:30 PM EDT
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Arcutis Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $37. The average 1-year stock price forecast is 40.85% higher than the current stock price, while the lowest is $34 (+29.43%) and the highest is $40 (+52.26%).
Price Target: $37 (+40.85%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Aug 11, 2026.
Analyst Ratings
The average analyst rating for Arcutis Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $34 | Buy | Reiterates | $34 | +29.43% | Aug 11, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $34 → $38 | Buy | Reiterates | $34 → $38 | +44.65% | Aug 6, 2026 |
| Needham | Needham | Buy Reiterates $40 | Buy | Reiterates | $40 | +52.26% | Aug 6, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $35 → $38 | Buy | Reiterates | $35 → $38 | +44.65% | Aug 6, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $35 | Buy | Maintains | $35 | +33.23% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
537.34M
from 376.07M
Increased by 42.88%
Revenue Next Year
686.92M
from 537.34M
Increased by 27.84%
EPS This Year
0.43
from -0.13
EPS Next Year
1.36
from 0.43
Increased by 216.28%
EPS and Forward PE are based on non-GAAP adjusted numbers.